June’s Triple Event for VanEck’s Dividend ETF: Payout, Rebalance, and a Five-Star Stamp of Approval

VanEck €7.5B dividend ETF goes ex-dividend 4 June with €0.90/share, backed by Morningstar's top rating and 17.9% annualized return – but RSI flags overbought at 83.8.

A crowded calendar is shaping up for the €7.5 billion VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF. The fund’s ex-dividend date falls on 4 June 2026, with an estimated payout of €0.90 per share — part of a total 12-month distribution of €1.74 that has been climbing at an annual rate of nearly 17% over the past three years. That same week also brings the index’s semi-annual rebalancing, making for an unusually dense stretch of corporate actions.

The timing coincides with a fresh seal of approval from Morningstar. The rating agency awarded the ETF its top five-star grade in May 2026, citing an “Above Average” investment process. The decision rests on a string of strong risk-adjusted returns: the fund’s annualised performance over five years stands at 17.9%, more than double the 8.3% average for its Morningstar category. Its gross information ratio has consistently ranked in the top decile over one, three and five years, underpinning the analyst judgment.

Those numbers are backed by a disciplined stock-picking framework. The index admits only companies that have maintained or grown their dividend per share over the past five years and keep their forward payout ratio below 75%. From that pool, the 100 highest-yielding securities are selected. The resulting portfolio is tilted heavily toward traditional sectors: financials account for 31% of the weight and energy for roughly a fifth. Top holdings include Exxon Mobil, TotalEnergies and Nestlé, while Pfizer sits as the largest single position at close to 4.7% of assets.

Pfizer’s recent quarterly report provides a tailwind ahead of the payout date. The drugmaker posted first-quarter revenue of $14.45 billion, up 5% year on year, and adjusted earnings per share of $0.75 — about 4% above analyst consensus. Management kept its full?year guidance unchanged at $59.5–$62.5 billion in sales and EPS of $2.80–$3.00. Notably, the segment of newly launched and acquired products saw operating growth of 22%, signalling further progress in reducing reliance on the Covid franchise.

The broader market environment is also supportive. US dividend-focused ETFs pulled in $24.1 billion during the first quarter of 2026, the strongest start to any year in four years, according to LSEG Lipper data. The rotation out of richly valued US tech stocks into capital?intensive sectors with reliable payouts has boosted the fund’s appeal. The MSCI All Country World ex?USA index has recently outperformed the S&P 500 by double?digit percentage points, a dynamic that directly benefits this ETF’s developed?world, non?US tilt.

Yet the rally has pushed the shares to $51.80, just 2% shy of the 52?week high of $52.93, and the relative strength index sits at 83.8 — a reading that flags an overbought condition. Whether that triggers profit?taking before the June events remains an open question.

For investors who prefer automatic reinvestment, VanEck introduced an accumulating twin on 23 April 2026. The TDVX ETF is domiciled in Ireland and trades on the Xetra and London Stock Exchanges, with the same 0.38% expense ratio and identical strategy — except that it excludes US stocks. The separate structure was necessary because the main fund’s Dutch domicile does not permit an accumulating share class, avoiding a disruptive restructuring for existing holders.